ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999

IOM Panel Suggest Ways To Fund More Training, Construction

November 9, 1990

NCCS Networker Volume 4 Issue 1, Winter 1990

January 13, 1990

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

New Biologic Therapies Showing Promise In A Variety Of Advanced Solid Tumors

June 29, 2001

Blinatumomab Shows Response In Adults with Refractory ALL

May 25, 2012